Novel Therapeutic Targets in Acute Myeloid Leukemia (AML)

Overview

Journal Curr Oncol Rep

Publisher Current Science

Specialty Oncology

Date 2024 Mar 19

PMID 38502417

Authors

Michael Wysota

Marina Konopleva

Shane Mitchell

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This review seeks to identify and describe novel genetic and protein targets and their associated therapeutics currently being used or studied in the treatment of acute myeloid leukemia (AML).

Recent Findings: Over the course of the last 5-6 years, several targeted therapies have been approved by the FDA, for the treatment of both newly diagnosed as well as relapsed/refractory AML. These novel therapeutics, as well as several others currently under investigation, have demonstrated activity in AML and have improved outcomes for many patients. Patient outcomes in AML have slowly improved over time, though for many patients, particularly elderly patients or those with relapsed/refractory disease, mortality remains very high. With the identification of several molecular/genetic drivers and protein targets and development of therapeutics which leverage those mechanisms to target leukemic cells, outcomes for patients with AML have improved and continue to improve significantly.

Citing Articles

Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies.

Platzbecker U, Larson R, Gurbuxani S Hemasphere. 2025; 9(2):e70083.

PMID: 39897085 PMC: 11783223. DOI: 10.1002/hem3.70083.

Discovery of 5-imidazole-3-methylbenz[d]isoxazole derivatives as potent and selective CBP/p300 bromodomain inhibitors for the treatment of acute myeloid leukemia.

Hu J, Tang X, Luo G, Zhang C, Wu T, Wang C Acta Pharmacol Sin. 2025; .

PMID: 39890943 DOI: 10.1038/s41401-025-01478-x.

A novel label-free method to determine equilibrium dissociation constants of antibodies binding to cell surface proteins.

Lacy E, Nanjunda R, Klakamp S, Kwok D, Nemeth J, Powers G Sci Rep. 2025; 15(1):3352.

PMID: 39870691 PMC: 11772844. DOI: 10.1038/s41598-024-82288-9.

Single-cell transcriptomics reveals heterogeneity and prognostic markers of myeloid precursor cells in acute myeloid leukemia.

He G, Jiang L, Zhou X, Gu Y, Tang J, Zhang Q Front Immunol. 2024; 15:1494106.

PMID: 39737198 PMC: 11683592. DOI: 10.3389/fimmu.2024.1494106.

Acute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.

Niscola P, Gianfelici V, Catalano G, Giovannini M, Mazzone C, Noguera N Curr Oncol. 2024; 31(11):6632-6658.

PMID: 39590121 PMC: 11592437. DOI: 10.3390/curroncol31110490.

References

Alotaibi A, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia T, DiNardo C . Patterns of Resistance Differ in Patients with Acute Myeloid Leukemia Treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Discov. 2021; 2(2):125-134. PMC: 7935111. DOI: 10.1158/2643-3230.BCD-20-0143. View

Im A, Sehgal A, Carroll M, Smith B, Tefferi A, Johnson D . DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia. 2014; 28(9):1774-83. PMC: 4234093. DOI: 10.1038/leu.2014.124. View

Erba H, Montesinos P, Kim H, Patkowska E, Vrhovac R, Zak P . Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10388):1571-1583. DOI: 10.1016/S0140-6736(23)00464-6. View

Zarnegar-Lumley S, Alonzo T, Gerbing R, Othus M, Sun Z, Ries R . Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis. Blood Adv. 2023; 7(19):5941-5953. PMC: 10562769. DOI: 10.1182/bloodadvances.2022008282. View

Schiller G, Tuttle P, Desai P . Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD-Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation. Biol Blood Marrow Transplant. 2016; 22(6):982-990. DOI: 10.1016/j.bbmt.2016.01.013. View

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N . Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016; 374(23):2209-2221. PMC: 4979995. DOI: 10.1056/NEJMoa1516192. View

Venugopal S, Takahashi K, Daver N, Maiti A, Borthakur G, Loghavi S . Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J. 2022; 12(1):10. PMC: 8789767. DOI: 10.1038/s41408-021-00604-2. View

Kindler T, Lipka D, Fischer T . FLT3 as a therapeutic target in AML: still challenging after all these years. Blood. 2010; 116(24):5089-102. DOI: 10.1182/blood-2010-04-261867. View

Kubasch A, Schulze F, Giagounidis A, Gotze K, Kronke J, Sockel K . Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2019; 34(4):1182-1186. PMC: 7214242. DOI: 10.1038/s41375-019-0645-z. View

10.

Jordan C, Upchurch D, Szilvassy S, Guzman M, Howard D, PETTIGREW A . The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000; 14(10):1777-84. DOI: 10.1038/sj.leu.2401903. View

11.

Pratz K, Cherry M, Altman J, Cooper B, Podoltsev N, Cruz J . Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML. J Clin Oncol. 2023; 41(26):4236-4246. DOI: 10.1200/JCO.22.02721. View

12.

Brunetti L, Gundry M, Sorcini D, Guzman A, Huang Y, Ramabadran R . Mutant NPM1 Maintains the Leukemic State through HOX Expression. Cancer Cell. 2018; 34(3):499-512.e9. PMC: 6159911. DOI: 10.1016/j.ccell.2018.08.005. View

13.

Krivtsov A, Armstrong S . MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007; 7(11):823-33. DOI: 10.1038/nrc2253. View

14.

Chan S, Thomas D, Corces-Zimmerman M, Xavy S, Rastogi S, Hong W . Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015; 21(2):178-84. PMC: 4406275. DOI: 10.1038/nm.3788. View

15.

Sasaki K, Ravandi F, Kadia T, DiNardo C, Short N, Borthakur G . De novo acute myeloid leukemia: A population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017. Cancer. 2021; 127(12):2049-2061. PMC: 11826308. DOI: 10.1002/cncr.33458. View

16.

. Safety Concerns Prompt Pause of Magrolimab Trials. Cancer Discov. 2022; 12(4):877-878. DOI: 10.1158/2159-8290.CD-NB2022-0012. View

17.

Rollig C, Serve H, Noppeney R, Hanoun M, Krug U, Baldus C . Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial. Leukemia. 2021; 35(9):2517-2525. PMC: 8410595. DOI: 10.1038/s41375-021-01148-x. View

18.

Frankel A, Liu J, Rizzieri D, Hogge D . Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2008; 49(3):543-53. DOI: 10.1080/10428190701799035. View

19.

Wang E, Montesinos P, Minden M, Lee J, Heuser M, Naoe T . Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy. Blood. 2022; 140(17):1845-1857. PMC: 10653009. DOI: 10.1182/blood.2021014586. View

20.

Ward P, Patel J, Wise D, Abdel-Wahab O, Bennett B, Coller H . The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17(3):225-34. PMC: 2849316. DOI: 10.1016/j.ccr.2010.01.020. View